FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019481173> ?p ?o ?g. }

• W2019481173 endingPage "e34834" @default.
• W2019481173 startingPage "e34834" @default.
• W2019481173 abstract "Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia and now is being recognized as an important neurotropic virus. Effective medications and prophylactic vaccine against EV71 infection are urgently needed. Based on the success of inactivated poliovirus vaccine, a prototype chemically inactivated EV71 vaccine candidate has been developed and currently in human phase 1 clinical trial.In this report, we present the development of a serum-free cell-based EV71 vaccine. The optimization at each step of the manufacturing process was investigated, characterized and quantified. In the up-stream process development, different commercially available cell culture media either containing serum or serum-free was screened for cell growth and virus yield using the roller-bottle technology. VP-SFM serum-free medium was selected based on the Vero cell growth profile and EV71 virus production. After the up-stream processes (virus harvest, diafiltration and concentration), a combination of gel-filtration liquid chromatography and/or sucrose-gradient ultracentrifugation down-stream purification processes were investigated at a pilot scale of 40 liters each. Although the combination of chromatography and sucrose-gradient ultracentrifugation produced extremely pure EV71 infectious virus particles, the overall yield of vaccine was 7-10% as determined by a VP2-based quantitative ELISA. Using chromatography as the downstream purification, the virus yield was 30-43%. To retain the integrity of virus neutralization epitopes and the stability of the vaccine product, the best virus inactivation was found to be 0.025% formalin-treatment at 37 °C for 3 to 6 days. Furthermore, the formalin-inactivated virion vaccine candidate was found to be stable for >18 months at 4 °C and a microgram of viral proteins formulated with alum adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates.These results provide valuable information supporting the current cell-based serum-free EV71 vaccine candidate going into human Phase I clinical trials." @default.
• W2019481173 created "2016-06-24" @default.
• W2019481173 creator A5001769670 @default.
• W2019481173 creator A5003491525 @default.
• W2019481173 creator A5004020400 @default.
• W2019481173 creator A5006191599 @default.
• W2019481173 creator A5006919277 @default.
• W2019481173 creator A5010229917 @default.
• W2019481173 creator A5010919871 @default.
• W2019481173 creator A5015881023 @default.
• W2019481173 creator A5026996154 @default.
• W2019481173 creator A5054217593 @default.
• W2019481173 creator A5066352409 @default.
• W2019481173 creator A5066493723 @default.
• W2019481173 creator A5070954081 @default.
• W2019481173 creator A5072592406 @default.
• W2019481173 creator A5076865412 @default.
• W2019481173 creator A5078795990 @default.
• W2019481173 creator A5079542961 @default.
• W2019481173 creator A5087480790 @default.
• W2019481173 date "2012-04-17" @default.
• W2019481173 modified "2023-10-14" @default.
• W2019481173 title "Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates" @default.
• W2019481173 cites W1969470610 @default.
• W2019481173 cites W1978042026 @default.
• W2019481173 cites W1987053779 @default.
• W2019481173 cites W1988381117 @default.
• W2019481173 cites W2016286674 @default.
• W2019481173 cites W2022776212 @default.
• W2019481173 cites W2038314679 @default.
• W2019481173 cites W2054095251 @default.
• W2019481173 cites W2055952761 @default.
• W2019481173 cites W2073166377 @default.
• W2019481173 cites W2088394825 @default.
• W2019481173 cites W2096586279 @default.
• W2019481173 cites W2099315132 @default.
• W2019481173 cites W2100008113 @default.
• W2019481173 cites W2104321589 @default.
• W2019481173 cites W2109993084 @default.
• W2019481173 cites W2111265624 @default.
• W2019481173 cites W2111820136 @default.
• W2019481173 cites W2153545807 @default.
• W2019481173 cites W2160788969 @default.
• W2019481173 cites W2315624236 @default.
• W2019481173 doi "https://doi.org/10.1371/journal.pone.0034834" @default.
• W2019481173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3328501" @default.
• W2019481173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22529942" @default.
• W2019481173 hasPublicationYear "2012" @default.
• W2019481173 type Work @default.
• W2019481173 sameAs 2019481173 @default.
• W2019481173 citedByCount "53" @default.
• W2019481173 countsByYear W20194811732012 @default.
• W2019481173 countsByYear W20194811732013 @default.
• W2019481173 countsByYear W20194811732014 @default.
• W2019481173 countsByYear W20194811732015 @default.
• W2019481173 countsByYear W20194811732016 @default.
• W2019481173 countsByYear W20194811732017 @default.
• W2019481173 countsByYear W20194811732018 @default.
• W2019481173 countsByYear W20194811732019 @default.
• W2019481173 countsByYear W20194811732020 @default.
• W2019481173 countsByYear W20194811732021 @default.
• W2019481173 countsByYear W20194811732022 @default.
• W2019481173 countsByYear W20194811732023 @default.
• W2019481173 crossrefType "journal-article" @default.
• W2019481173 hasAuthorship W2019481173A5001769670 @default.
• W2019481173 hasAuthorship W2019481173A5003491525 @default.
• W2019481173 hasAuthorship W2019481173A5004020400 @default.
• W2019481173 hasAuthorship W2019481173A5006191599 @default.
• W2019481173 hasAuthorship W2019481173A5006919277 @default.
• W2019481173 hasAuthorship W2019481173A5010229917 @default.
• W2019481173 hasAuthorship W2019481173A5010919871 @default.
• W2019481173 hasAuthorship W2019481173A5015881023 @default.
• W2019481173 hasAuthorship W2019481173A5026996154 @default.
• W2019481173 hasAuthorship W2019481173A5054217593 @default.
• W2019481173 hasAuthorship W2019481173A5066352409 @default.
• W2019481173 hasAuthorship W2019481173A5066493723 @default.
• W2019481173 hasAuthorship W2019481173A5070954081 @default.
• W2019481173 hasAuthorship W2019481173A5072592406 @default.
• W2019481173 hasAuthorship W2019481173A5076865412 @default.
• W2019481173 hasAuthorship W2019481173A5078795990 @default.
• W2019481173 hasAuthorship W2019481173A5079542961 @default.
• W2019481173 hasAuthorship W2019481173A5087480790 @default.
• W2019481173 hasBestOaLocation W20194811731 @default.
• W2019481173 hasConcept C14086860 @default.
• W2019481173 hasConcept C159047783 @default.
• W2019481173 hasConcept C185592680 @default.
• W2019481173 hasConcept C18743360 @default.
• W2019481173 hasConcept C2522874641 @default.
• W2019481173 hasConcept C2777888124 @default.
• W2019481173 hasConcept C2778889330 @default.
• W2019481173 hasConcept C2779261636 @default.
• W2019481173 hasConcept C41625074 @default.
• W2019481173 hasConcept C43617362 @default.
• W2019481173 hasConcept C48314217 @default.
• W2019481173 hasConcept C54689828 @default.
• W2019481173 hasConcept C55493867 @default.
• W2019481173 hasConcept C67568554 @default.
• W2019481173 hasConcept C86803240 @default.

• next